

# Natural History and Epidemiology of Lung Cancer

Panos Fidias, MD

University of Arizona Cancer Center at  
St. Joseph's Hospital and Medical Center



# Natural History and the Epidemiology of Lung Cancer

Panos Fidas MD

Thoracic Oncology

University of Arizona Cancer Center at Dignity

Associate Professor of Medicine

College of Medicine - Phoenix



**Dignity Health**<sup>TM</sup>

St. Joseph's Hospital and  
Medical Center




# Disease Characteristics for Screening

---

- Prevalent
- Serious
- Defined risk factors
- Stage-dependent survival
- Established detection method
- Defined premalignant lesions


# Primary Cancers of the Lung

Non-Small Cell Lung Cancer




85% of cancers  
Typically aggressive  
Surgery or  
Chemotherapy

Small Cell Lung Cancer




15% of cancers  
Typically very aggressive  
Chemotherapy

Carcinoid



Typically very indolent  
Surgery


# 2011 Estimated US Cancer Cases



Source: American Cancer Society, 2011

Source: American Cancer Society, 2011.

# Lifetime Probability of Developing Cancer 2005-2007




# Cancer Death Rates Among Men, 1930-2007

---




# Cancer Death Rates Among Women, 1930-2007






# Lung Cancer Survival By Stage



# Cancer Mortality




# Incidental Lung Cancer


---

- Autopsy study
  - 24708 cases; 56% estimated natural causes
  - Incidental lung cancer in 0.34%
  - Incidental non-small cell lung cancer in 0.2%
- 
- Prostate cancer
  - Men older than 50: 23-46% of autopsies


# Causes of Lung Cancer



# Tobacco Use in the US, 1900-2006




# Declining Risk After Quitting Smoking









# Risk of Malignancy: Smoking History

per 100,000 person years



# Disease Characteristics for Screening: Lung Cancer

---

- Prevalent 
- Serious 
- Defined risk factors 
- Stage-dependent survival 
- Established detection method 
- Defined premalignant lesions 




# Timeline of Screening Studies




# Lung Cancer Screening Studies: PLCO

---



# PLCO: Lung Cancer Mortality by Year




## PLCO: Lung Cancer Cases

	Screened	Control
N	77445	77456
Lung Cancer Cases	1696	1620
Small Cell	14%	15%
NSCLC		
Stage I	32%	27%
Stage II	8%	8%
Stage III	25%	26%
Stage IV	35%	38%
Screen Detected	18%	N/a


## Low Dose CT scan

---


- No strict definition of low dose CT
- Non contrast scan
- Generally, 10-30% of standard-dose CT scan
- Compared to high resolution CT scan:
  - As accurate for detecting solid pulmonary nodules
  - Less sensitive for low density lesions (GGOs)
- Thin sections (1 mm) can improve definition of subsolid nodules




# Lung Cancer Screening Studies: NLST



# NLST: Cumulative Number of Lung Cancers



# NLST: Deaths from Lung Cancers





## NLST: Lung Cancer Cases

	CT	CxR
N	26,309	26,035
Lung Cancer Cases	1060	941
Small Cell	13.1%	17.1%
NSCLC		
Stage I	50%	31.1%
Stage II	7.1%	7.9%
Stage III	21.2%	24.8%
Stage IV	21.7%	36.1%
Screen Detected	61.2%	29.6%

# Who Should Be Screened?

---

## National Lung Screening Trial

- Age 55 – 74
- Cigarette smoking of at least 30 pack years
- Quit smoking within 15 years
- No history of lung cancer, chest CT within 18 months, hemoptysis, unexplained weight loss of 15 lb. in the preceding year

# Society Recommendations

---

The NCCN Lung Cancer Screening Panel **recommends lung cancer screening** using helical LDCT for individuals with ... high risk factors

ASCO suggests that annual screening with LDCT **should be offered over both annual screening with chest radiograph or no screening**, but only in settings that can deliver the comprehensive care provided to NLST participants.

Practice Guideline of the American College of Chest Physicians  
and the American Society of Clinical Oncology

NCCN Lung Cancer Screening Version 1.2013

<http://www.asco.org/institute-quality/role-ct-screening-lung-cancer-clinical-practice-evidence-based-practice-guideline>

# Society Recommendations

---

## American Association for Thoracic Surgery

Guidelines **call for annual lung cancer screening with low-dose CT** for North Americans from age 55-79 years with a 30 pack-year history of smoking. Lung cancer survivors should have annual low-dose CT until the age of 79 years. Annual low-dose CT should be offered starting at age 50 years with 20 pack-years if there is a risk of developing lung cancer of 5% or greater over the following 5 years

## US Preventive Services Task Force

The USPSTF **recommends annual screening for lung cancer with low-dose computed tomography in adults ages 55 to 80 years** who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery

Jaklitsch et al. J Thorac Cardiovasc Surg 144: 33, 2012

<http://www.uspreventiveservicestaskforce.org/uspstf/uspslung.htm> Release Date: December 2013

# Centers for Medicare & Medicaid Services (CAG-00439N)

---

- Approved February 2015;
- Age 55 – 74 years (proposed);
- Age 55 – 77 years (final);
- Asymptomatic (no signs or symptoms of lung disease);
- Tobacco smoking history of at least 30 pack-years (one pack-year = smoking one pack per day for one year; 1 pack = 20 cigarettes);
- Current smoker or one who has quit smoking within the last 15 years

<http://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=274>

[http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274&NcaName=Screening+for+Lung+Cancer+with+Low+Dose+Computed+Tomography+\(LDCT\)&TimeFrame=7&DocType=All&bc=AQAAIAAAAgAAAA%3d%3d&](http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274&NcaName=Screening+for+Lung+Cancer+with+Low+Dose+Computed+Tomography+(LDCT)&TimeFrame=7&DocType=All&bc=AQAAIAAAAgAAAA%3d%3d&)

# Lung Cancer Risk Factors

---


- Increasing age
- Chronic obstructive pulmonary disease
- Pulmonary fibrosis
- Personal history of cancer
- Family history of lung cancer
- Smoking status

# Prediction Model-Based Screening Eligibility

Variable	Odds Ratio (95% CI)	P Value	Beta Coefficient
Age, per 1-yr increase†	1.081 (1.057–1.105)	<0.001	0.0778868
Race or ethnic group‡			
White	1.000		Reference group
Black	1.484 (1.083–2.033)	0.01	0.3944778
Hispanic	0.475 (0.195–1.160)	0.10	–0.7434744
Asian	0.627 (0.332–1.185)	0.15	–0.466585
American Indian or Alaskan Native	1		0
Native Hawaiian or Pacific Islander	2.793 (0.992–7.862)	0.05	1.027152
Education, per increase of 1 level†§	0.922 (0.874–0.972)	0.003	–0.0812744
Body-mass index, per 1-unit increase†	0.973 (0.955–0.991)	0.003	–0.0274194
Chronic obstructive pulmonary disease (yes vs. no)	1.427 (1.162–1.751)	0.001	0.3553063
Personal history of cancer (yes vs. no)	1.582 (1.172–2.128)	0.003	0.4589971
Family history of lung cancer (yes vs. no)	1.799 (1.471–2.200)	<0.001	0.587185
Smoking status (current vs. former)	1.297 (1.047–1.605)	0.02	0.2597431
Smoking intensity¶			–1.822606
Duration of smoking, per 1-yr increase†	1.032 (1.014–1.051)	0.001	0.0317321
Smoking quit time, per 1-yr increase†	0.970 (0.950–0.990)	0.003	–0.0308572
Model constant			–4.532506

# Online Prediction Calculators

Probability of Lung Cancer Diagnosis by Risk Model  
**67 y/o male former smoker at 20 cigarettes per day for 40 years (40 pack-years)**





# PLCO<sub>m2012</sub> versus USPSTF

PLCO <sub>m2012</sub> risk	USPSTF Criteria Negative	USPSTF Criteria Positive	Total
PLCO <sub>m2012</sub> risk $\geq 0.0151$ negative	<i>n</i> = 20,712 (cell percent = 55.5%) Lung cancers = 101 Lung cancer deaths = 141 (a)	<i>n</i> = 3,695 (cell percent = 9.9%) <b>Lung cancers = 33</b> <b>Lung cancer deaths = 48</b> (b)	<i>n</i> = 24,407 (column percent = 65.4%) Lung cancers = 135 Lung cancer deaths = 189
PLCO <sub>m2012</sub> risk $\geq 0.0151$ positive	<i>n</i> = 2,445 (cell percent = 6.6%) <b>Lung cancers = 93</b> <b>Lung cancer deaths = 102</b> (c)	<i>n</i> = 10,475 (cell percent = 28.1%) Lung cancers = 449 Lung cancer deaths = 554 (d)	<i>n</i> = 12,920 (column percent = 34.6%) Lung cancers = 542 Lung cancer deaths = 656
Total	<i>n</i> = 23,157 (row percent = 62.0%) Lung cancers = 195 Lung cancer deaths = 243	<i>n</i> = 14,170 (row percent = 38.0%) Lung cancers = 482 Lung cancer deaths = 602	<i>N</i> = 37,327 (cell percent = 100%) Lung cancers = 677 Lung cancer deaths = 845


## PLCO<sub>m2012</sub> versus USPSTF

---

- PLCO<sub>m2012</sub>
  - Selected 8.8% fewer individuals for screening
  - Identified 12.4% more lung cancers
  - Had higher PPV (4.2% versus 3.4%)
  - 26% of USPSTF positive individuals have risks below PLCO<sub>m2012</sub> threshold
  - 8.5% of PLCO former smokers who quit > 15 years had PLCO<sub>m2012</sub> risk above threshold

# Smoking Cessation in Screened Populations

- PLCO:
  - 6807 current smokers
    - 65.2% ongoing smoking
    - Younger, black or Hispanic, less educated, unmarried, lower income, lower BMI and no family history of lung cancer
- NLST:
  - 14661 current smokers
    - 76.5% ongoing smoking at 3 years
    - Lower with positive finding suspicious for lung cancer



# Smoking Cessation in Lung Cancer Patients

---

- 154 early stage non-small cell lung cancer patients
- At 12 months after surgery 36.9% were smoking
- 60% of patients lapsed within the first 2 months
- Predictors
  - Shorter quit duration
  - Intense appetite cravings
  - Lower income
  - Higher level of education

# Thank You